Search

Search Constraints

You searched for: Author/Creator Nisenbaum, B.

Search Results

1. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Issue 3 (September 2015)

2. 1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score. (September 2015)